Clinical trial
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
NCT06667908 is registered in ClinicalTrials.gov with Johnson & Johnson Enterprise Innovation Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 6, 2024
- Completion date
- December 31, 2028
- Enrollment
- 130 (estimated)
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.